Disclosures for "Effectiveness and Optimization of Low-sodium Oxybate in Participants with Narcolepsy Switching from Sodium Oxybate: Final Data from the Substitution of Equal Grams of Uninterrupted Xyrem to Xywav (SEGUE) Study"
-
Dr. Macfadden has received personal compensation for serving as an employee of Jazz pharma. Dr. Macfadden has stock in Jazz pharma.
-
Dr. Leary has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Dr. Leary has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Proper. Dr. Leary has stock in Jazz Pharmaceuticals.
-
Mr. Pfister has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Mr. Pfister has stock in Jazz Pharmaceuticals.
-
Mr. Fuller has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Mr. Fuller has received stock or an ownership interest from D F.